Farah Yusuf Mohamud Mohamed, Garad Mohamed Yahye, Mohamed Ali Abdiladhif, Ali Adam Bakar
Mogadishu Somali-Turkish Training and Research Hospital, Mogadishu, Somalia.
Infect Drug Resist. 2020 Jul 29;13:2631-2635. doi: 10.2147/IDR.S263632. eCollection 2020.
The purpose of this study was to identify the common clinical presentations and the evidence on the presence of ageusia and anosmia as an emerging coronavirus disease 2019 (COVID-19) symptom to better inform in both COVID-19 patients and clinicians.
As part of a double-institutional collaboration coordinated by doctors, this study retrospectively collected and analyzed the clinical characteristics of 60 patients with COVID-19 pneumonia between April 1 and April 20, 2020. Pregnant women and patients taking anti-cancer drugs had been excluded from the study. Data from each institution's electronic medical record had been obtained.
Sixty patients who had RT-PCR positive for COVID-19 were included in this study; of these patients, all of them had unknown exposure to COVID-19. The mean (SD) age was 45.7 (13.5) years, and 42 were men (70%). Of these patients, 80% had at least ageusia or anosmia. The most common symptoms at the onset of illness were cough (75%), fever (71.3%), myalgia or fatigue (53.3%), anosmia (loss of smell) (40%), ageusia (loss of taste) (28.3%), sore throat (25%), shortness of breath (16.7%), headache (16.7%), and GI symptoms (diarrhea, nausea, vomiting and loss appetite) (16.7%). A total of 68.3% of COVID-19 infected patients had reported either loss of taste or smell, and about 33.3% of them had only loss of smell, while 23.3% of them had impaired taste, and 11.7% of COVID-19 infected patients had both taste and smell loss.
During the epidemic period of SARS-CoV-2 infection, when presenting patients with ageusia and anosmia, physicians should consider COVID-19 pneumonia as a differential diagnosis to achieve early identification, avoid the delayed diagnosis, and prevention of transmission.
本研究旨在确定常见的临床表现以及作为新型冠状病毒肺炎(COVID-19)一种新出现症状的嗅觉减退和味觉减退的相关证据,以便更好地为COVID-19患者和临床医生提供信息。
作为由医生协调的双机构合作的一部分,本研究回顾性收集并分析了2020年4月1日至4月20日期间60例COVID-19肺炎患者的临床特征。孕妇和正在服用抗癌药物的患者被排除在研究之外。已获取各机构电子病历中的数据。
本研究纳入了60例COVID-19核酸检测呈阳性的患者;在这些患者中,所有人均无明确的COVID-19暴露史。平均(标准差)年龄为45.7(13.5)岁,男性42例(70%)。在这些患者中,80%至少有嗅觉减退或味觉减退。发病时最常见的症状为咳嗽(75%)、发热(71.3%)、肌痛或疲劳(53.3%)、嗅觉减退(嗅觉丧失)(40%)、味觉减退(味觉丧失)(28.3%)、咽痛(25%)、呼吸急促(16.7%)、头痛(16.7%)以及胃肠道症状(腹泻、恶心、呕吐和食欲不振)(16.7%)。共有68.3%的COVID-19感染患者报告有味觉或嗅觉丧失,其中约33.3%仅有嗅觉丧失,23.3%有味觉受损,11.7%的COVID-19感染患者味觉和嗅觉均丧失。
在严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染流行期间,当患者出现味觉减退和嗅觉减退时,医生应将COVID-19肺炎作为鉴别诊断考虑,以实现早期识别,避免延迟诊断,并防止传播。